AP3140A - Production of polio virus at high titers for vaccine production - Google Patents

Production of polio virus at high titers for vaccine production

Info

Publication number
AP3140A
AP3140A AP2012006075A AP2012006075A AP3140A AP 3140 A AP3140 A AP 3140A AP 2012006075 A AP2012006075 A AP 2012006075A AP 2012006075 A AP2012006075 A AP 2012006075A AP 3140 A AP3140 A AP 3140A
Authority
AP
ARIPO
Prior art keywords
production
high titers
polio virus
vaccine
vaccine production
Prior art date
Application number
AP2012006075A
Other languages
English (en)
Other versions
AP2012006075A0 (en
Inventor
John Alfred Lewis
Original Assignee
Crucell Holland Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Crucell Holland Bv filed Critical Crucell Holland Bv
Publication of AP2012006075A0 publication Critical patent/AP2012006075A0/xx
Application granted granted Critical
Publication of AP3140A publication Critical patent/AP3140A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/02—Recovery or purification
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/125—Picornaviridae, e.g. calicivirus
    • A61K39/13—Poliovirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32611—Poliovirus
    • C12N2770/32634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32611—Poliovirus
    • C12N2770/32651—Methods of production or purification of viral material
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AP2012006075A 2009-07-16 2010-07-08 Production of polio virus at high titers for vaccine production AP3140A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US27103809P 2009-07-16 2009-07-16
EP09165620 2009-07-16
PCT/EP2010/059796 WO2011006823A1 (en) 2009-07-16 2010-07-08 Production of polio virus at high titers for vaccine production

Publications (2)

Publication Number Publication Date
AP2012006075A0 AP2012006075A0 (en) 2012-02-29
AP3140A true AP3140A (en) 2015-02-28

Family

ID=41412431

Family Applications (1)

Application Number Title Priority Date Filing Date
AP2012006075A AP3140A (en) 2009-07-16 2010-07-08 Production of polio virus at high titers for vaccine production

Country Status (32)

Country Link
US (4) US8546123B2 (es)
EP (1) EP2454364B1 (es)
JP (1) JP5845178B2 (es)
KR (1) KR101548790B1 (es)
CN (1) CN102482647B (es)
AP (1) AP3140A (es)
AR (1) AR077314A1 (es)
AU (1) AU2010272685B2 (es)
BR (1) BR112012000942B8 (es)
CA (1) CA2763091C (es)
CO (1) CO6491042A2 (es)
CU (1) CU20120006A7 (es)
DK (1) DK2454364T3 (es)
EA (1) EA020563B1 (es)
ES (1) ES2484093T3 (es)
HR (1) HRP20140597T1 (es)
IL (1) IL217465A (es)
MA (1) MA33429B1 (es)
MX (1) MX2011012648A (es)
MY (1) MY183385A (es)
NZ (1) NZ596880A (es)
PE (1) PE20120571A1 (es)
PL (1) PL2454364T3 (es)
PT (1) PT2454364E (es)
RS (1) RS53377B (es)
SG (1) SG177655A1 (es)
SI (1) SI2454364T1 (es)
SM (1) SMT201400079B (es)
TN (1) TN2011000628A1 (es)
TW (1) TWI477606B (es)
WO (1) WO2011006823A1 (es)
ZA (1) ZA201108271B (es)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009532352A (ja) 2006-03-31 2009-09-10 ダブリュエーアールエフ−ウィスコンシン アラムナイ リサーチ ファウンデーション ワクチンのための高力価組み換えインフルエンザ・ウィルス
US9474798B2 (en) 2007-06-18 2016-10-25 Wisconsin Alumni Research Foundation Influenza M2 protein mutant viruses as live influenza attenuated vaccines
WO2010060719A1 (en) 2008-11-03 2010-06-03 Crucell Holland B.V. Method for the production of adenoviral vectors
PE20120571A1 (es) 2009-07-16 2012-06-06 Crucell Holland Bv Produccion de titulos elevados de polivirus para la produccion de vacunas
ES2813347T3 (es) 2009-10-26 2021-03-23 Wisconsin Alumni Res Found Virus recombinantes de la influenza de alto título con replicación mejorada en células Vero
US10130697B2 (en) 2010-03-23 2018-11-20 Wisconsin Alumni Research Foundation (Warf) Vaccines comprising mutant attenuated influenza viruses
ES2655051T3 (es) 2011-08-26 2018-02-16 Wisconsin Alumni Research Foundation Virus de la gripe con segmento génico PB2 mutante como vacunas vivas atenuadas
RU2015137703A (ru) * 2013-02-05 2017-03-09 Юниверсити Оф Джорджиа Рисерч Фаундейшн, Инк. Линии клеток для получения вирусов и способы их применения
EP2863943B1 (en) 2013-03-08 2016-07-13 Crucell Holland B.V. Acellular pertussis vaccine
KR20140112255A (ko) 2013-03-13 2014-09-23 고려대학교 산학협력단 바이러스 생산능이 증가된 세포주 및 그 제조방법
CN105121634B (zh) 2013-03-13 2019-07-26 易木农麦克斯有限公司 具有提高的病毒生产能力的细胞系及其生产方法
GB201305361D0 (en) 2013-03-25 2013-05-08 Univ Edinburgh Enhanced expression
PT3010537T (pt) 2013-06-17 2019-12-03 De Staat Der Nederlanden Vert Door De Mini Van Vws Miniie Van Volksgezondheid Welzijn En Sport Métodos para a prevenção da agregação de componentes virais
AU2014290203B2 (en) 2013-07-15 2020-12-24 Wisconsin Alumni Research Foundation High titer recombinant influenza viruses with enhanced replication in MDCK or vero cells or eggs
US20160053281A1 (en) * 2013-08-15 2016-02-25 The University Court Of The University Of Edinburgh Enhanced Expression Of RNA Vectors
JP6783143B2 (ja) 2014-03-25 2020-11-11 テルモ ビーシーティー、インコーポレーテッド 培地の受動的補充
EA039012B1 (ru) 2014-06-17 2021-11-22 Янссен Вэксинс Энд Превеншн Б.В. Рекомбинантный аттенуированный термочувствительный штамм полиовируса, содержащая его композиция, инактивированная полиомиелитная вакцина и комбинированная вакцина, способы их получения
WO2015194770A1 (ko) 2014-06-18 2015-12-23 고려대학교산학협력단 Bst2 유전자의 기능이 상실된 세포주를 이용한 바이러스 감염 촉진 및 생산 증진 방법
US10053671B2 (en) 2014-06-20 2018-08-21 Wisconsin Alumni Research Foundation (Warf) Mutations that confer genetic stability to additional genes in influenza viruses
EP3172317B1 (en) 2014-07-24 2019-05-01 Janssen Vaccines & Prevention B.V. Process for the purification of poliovirus from cell cultures
US10633422B2 (en) 2015-06-01 2020-04-28 Wisconsin Alumni Research Foundation (Warf) Influenza virus replication by inhibiting microRNA lec7C binding to influenza viral cRNA and mRNA
WO2017004592A1 (en) 2015-07-02 2017-01-05 Terumo Bct, Inc. Cell growth with mechanical stimuli
WO2017007839A1 (en) 2015-07-06 2017-01-12 Wisconsin Alumni Research Foundation (Warf) Improved influenza virus replication for vaccine development
AU2017221444B2 (en) 2016-02-19 2021-07-29 Wisconsin Alumni Research Foundation (Warf) Improved influenza B virus replication for vaccine development
US11965175B2 (en) 2016-05-25 2024-04-23 Terumo Bct, Inc. Cell expansion
US11685883B2 (en) 2016-06-07 2023-06-27 Terumo Bct, Inc. Methods and systems for coating a cell growth surface
US11104874B2 (en) 2016-06-07 2021-08-31 Terumo Bct, Inc. Coating a bioreactor
US10372100B2 (en) * 2016-08-29 2019-08-06 Ge Healthcare Bio-Sciences Corp. Manufacturing system for biopharmaceutical products
US11629332B2 (en) 2017-03-31 2023-04-18 Terumo Bct, Inc. Cell expansion
CN107723279B (zh) * 2017-10-18 2020-11-10 成都远睿生物技术有限公司 一种缺陷型腺病毒AdC68-GP的培养方法
US11197926B2 (en) 2017-10-25 2021-12-14 Wisconsin Alumni Research Foundation (Warf) Recombinant influenza viruses with stabilized HA for replication in eggs
EP3749757A4 (en) 2018-02-07 2021-11-24 Bharat Biotech International Limited PROCESS FOR PURIFICATION AND INACTIVATION OF ENTERVIRUSES AND VACCINE COMPOSITIONS OBTAINED THEREOF
US12343390B2 (en) 2018-08-07 2025-07-01 Wisconsin Alumni Research Foundation (Warf) Recombinant biologically contained filovirus vaccine
US11389523B2 (en) 2018-08-20 2022-07-19 Wisconsin Alumni Research Foundation (Warf) Vectors for eliciting immune responses to non-dominant epitopes in the hemagglutinin (HA) protein
EP3914295A2 (en) 2019-01-23 2021-12-01 Yoshihiro Kawaoka Mutations that confer genetic stability to additional genes in influenza viruses
CN113874496A (zh) 2019-02-08 2021-12-31 威斯康星校友研究基金会(Warf) 人源化细胞系
WO2020223699A1 (en) 2019-05-01 2020-11-05 Wisconsin Alumni Research Foundation (Warf) Improved influenza virus replication for vaccine development
WO2020229581A1 (en) 2019-05-16 2020-11-19 Janssen Vaccines & Prevention B.V. Methods for inducing a safe immune response against polio virus
JP7627911B2 (ja) 2019-08-27 2025-02-07 ウィスコンシン アルムニ リサーチ ファンデイション 卵内複製のための安定化されたｈａを持つ組換えインフルエンザウイルス
WO2021150874A1 (en) 2020-01-24 2021-07-29 Wisconsin Alumni Research Foundation (Warf) Recombinant influenza viruses with stabilized na
WO2021195410A1 (en) 2020-03-25 2021-09-30 Wisconsin Alumni Research Foundation (Warf) Recombinant multivalent influenza viruses

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4525349A (en) * 1981-12-29 1985-06-25 Societe Anonyme Dite: Institut Merueux Process for the large-scale production of a vaccine against poliomyelitis and the resulting vaccine
ATE445705T1 (de) 1995-06-15 2009-10-15 Crucell Holland Bv Verpackungssysteme für humane rekombinante adenoviren zur gentherapie
US7521220B2 (en) * 1999-11-26 2009-04-21 Crucell Holland B.V. Production of vaccines
EP1103610A1 (en) * 1999-11-26 2001-05-30 Introgene B.V. Production of vaccines from immortalised mammalian cell lines
US6544424B1 (en) 1999-12-03 2003-04-08 Refined Technology Company Fluid filtration system
EP1256803A1 (en) 2001-05-07 2002-11-13 Crucell Holland B.V. Methods for the identification of antiviral compounds
AU2003288273A1 (en) * 2002-10-23 2004-05-13 Crucell Holland B.V. New settings for recombinant adenoviral-based vaccines
WO2004055187A1 (en) * 2002-12-17 2004-07-01 Crucell Holland B.V. Recombinant viral-based malaria vaccines
CN100383238C (zh) * 2003-05-09 2008-04-23 克鲁塞尔荷兰公司 E1-永生化的细胞培养物及培养所述细胞以提高从中获取的产物产量的方法
CN104388324A (zh) 2004-03-05 2015-03-04 帝斯曼知识产权资产管理有限公司 用于通过连续灌注和交互切向流来培养细胞的方法
MX2007002372A (es) 2004-08-27 2007-05-08 Panacea Biotec Ltd Vacuna para la poliomielitis inactivada derivada de la cepa sabin del virus de la polio.
ES2371175T3 (es) * 2004-10-14 2011-12-28 Crucell Holland B.V. Vacunas de sensibilización/refuerzo de malaria.
CN100500827C (zh) * 2004-11-26 2009-06-17 中国医学科学院医学生物学研究所 用人胚肺二倍体细胞培养繁殖脊髓灰质炎病毒的方法
US20100144620A1 (en) * 2006-11-16 2010-06-10 Crucell Holland B.V. Complementation of factor xi deficeincy by factor v mutants
PE20120571A1 (es) 2009-07-16 2012-06-06 Crucell Holland Bv Produccion de titulos elevados de polivirus para la produccion de vacunas
KR20120070015A (ko) 2010-12-21 2012-06-29 (주)창조바이오텍 알파-피넨을 유효성분으로 포함하는 스쿠티카충 구제용 조성물

Also Published As

Publication number Publication date
CA2763091C (en) 2019-07-23
EA020563B1 (ru) 2014-12-30
RS53377B (sr) 2014-10-31
ES2484093T3 (es) 2014-08-11
AU2010272685A1 (en) 2011-12-08
HK1164922A1 (en) 2012-09-28
US9022240B2 (en) 2015-05-05
ZA201108271B (en) 2012-07-25
CA2763091A1 (en) 2011-01-20
PT2454364E (pt) 2014-07-04
CN102482647A (zh) 2012-05-30
US20130273106A1 (en) 2013-10-17
IL217465A0 (en) 2012-02-29
CU20120006A7 (es) 2012-10-15
US8546123B2 (en) 2013-10-01
AP2012006075A0 (en) 2012-02-29
MA33429B1 (fr) 2012-07-03
JP5845178B2 (ja) 2016-01-20
US20140242670A1 (en) 2014-08-28
WO2011006823A1 (en) 2011-01-20
CN102482647B (zh) 2015-12-16
US20110027317A1 (en) 2011-02-03
MY183385A (en) 2021-02-18
SMT201400079B (it) 2014-09-08
KR101548790B1 (ko) 2015-08-31
TWI477606B (zh) 2015-03-21
JP2012532616A (ja) 2012-12-20
SG177655A1 (en) 2012-02-28
TW201118173A (en) 2011-06-01
SI2454364T1 (sl) 2014-08-29
IL217465A (en) 2016-05-31
PE20120571A1 (es) 2012-06-06
EP2454364A1 (en) 2012-05-23
TN2011000628A1 (en) 2013-05-24
NZ596880A (en) 2013-10-25
HRP20140597T1 (hr) 2014-09-12
BR112012000942A2 (pt) 2016-03-15
MX2011012648A (es) 2012-01-12
EA201270173A1 (ru) 2012-06-29
KR20120033334A (ko) 2012-04-06
BR112012000942B1 (pt) 2020-10-27
US20130052224A1 (en) 2013-02-28
BR112012000942B8 (pt) 2021-05-25
DK2454364T3 (da) 2014-07-21
EP2454364B1 (en) 2014-04-23
AR077314A1 (es) 2011-08-17
AU2010272685B2 (en) 2015-02-26
CO6491042A2 (es) 2012-07-31
PL2454364T3 (pl) 2014-09-30

Similar Documents

Publication Publication Date Title
AP3140A (en) Production of polio virus at high titers for vaccine production
ZA201202836B (en) Method of preparing plant-derived vlps
HUS1700002I1 (hu) Hepatitis C vírus replikációjának inhibitorai
ZA201202758B (en) Stabilising excipient for inactivated whole-virus vaccines
PT2634191E (pt) Processo para preparar derivados de tienopirimidinadiona
ZA201101645B (en) Process for prodcution of vaccines
GB0918679D0 (en) Influenza vaccine
EP2488185A4 (en) INFECTIOUS TORQUE TENO VIRUS CLONE
GB2467215B (en) Burkholderia components vaccine
ZA201008125B (en) Inactivated live-attenuated bluetongue virus vaccine
GB0714489D0 (en) Process for preparing viral vaccine
ZA201203862B (en) Dna vaccine against virus of yellow fever
GB0920319D0 (en) HPV vaccine
GB0903910D0 (en) Vaccine production